Cyclo Therapeutics (CYTHW) Stock Analysis
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
What Cyclo Therapeutics does
Cyclo Therapeutics, Inc. is dedicated to developing biopharmaceutical treatments derived from cyclodextrin to combat various illnesses. A central component of their research and development pipeline is Trappsol Cyclo, a therapeutic specifically targeting Niemann-Pick Type C disease and Alzheimer's disease. Charles E. Rick Strattan founded the company on August 9, 1990, and it is presently based in Gainesville, Florida.
Key metrics
ETFs linked to CYTHW
Broad-market and Healthcare sector ETFs an investor holding Cyclo Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how CYTHW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CYTHW in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Cyclo Therapeutics?
- Cyclo Therapeutics trades under the ticker CYTHW on NASDAQ.
- Which exchange is CYTHW listed on?
- CYTHW is listed on NASDAQ.
- What sector does Cyclo Therapeutics operate in?
- Cyclo Therapeutics is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
- How can PortView help analyze CYTHW in a portfolio?
- PortView shows CYTHW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.